Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide Alfa for Prediabetes Reversal (Randomized Double-Blind Placebo-Controlled Trial)
ChiCTR2600130237Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in prediabetes comparing Efsubaglutide Alfa + Lifestyle with Placebo + Lifestyle (2 arms). Primary endpoint: Remission rate of prediabetes after 24 weeks of treatment. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
efsubaglutide alfa
03
Conditions
prediabetes
Beyond the preview
Go deeper on ChiCTR2600130237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130237.